Preclinical data suggest that chemoradiotherapy may up‐regulate PD‐L1 expression in tumor cells, and the phase 3 study proved that PD‐L1 blockade can help restore systemic and long‐term immune response after chemoradiotherapy. The gene discussed is CD274; the disease is neoplasm.